Anti-CD28 Antibodies Modify Regulatory Mechanisms and Reinforce Tolerance in CD40Ig-Treated Heart Allograft Recipients

Carole Guillonneau, Céline Séveno, Anne-Sophie Dugast, Xian-Liang Li, Karine Renaudin, Fabienne Haspot, Claire Usal, Joëlle Veziers, Ignacio Anegon and Bernard Vanhove

_J Immunol_ 2007; 179:8164-8171; doi: 10.4049/jimmunol.179.12.8164

http://www.jimmunol.org/content/179/12/8164
Anti-CD28 Antibodies Modify Regulatory Mechanisms and Reinforce Tolerance in CD40Ig-Treated Heart Allograft Recipients

Carole Guillonneau,²* Céline Séveno,²* Anne-Sophie Dugast,* Xian-Liang Li,* Karine Renaudin,† Fabienne Haspot,* Claire Usal,* Joëlle Veziers,* Ignacio Anegon,³,4* and Bernard Vanhove³,4*

Blockade of CD40-CD40 ligand (CD40L) costimulation has been shown to synergize with that of CTLA4/CD28-B7 to promote transplant tolerance. To date, however, CD28-B7 interactions have been prevented using B7-blocking reagents like CTLA4-Ig that inhibit CD28-B7 together with CD40-Ig interactions. In this study, we have tested anti-CD28 Abs to prevent selectively CD28-B7 interactions while preserving CTLA4-B7 in addition to CD40-CD40L blockade. In the LEW.1W to LEW.1A rat combination, interfering with CD40-CD40L interactions by CD40Ig administration through gene transfer resulted in indefinite heart allograft survival due to the appearance of clonotypic CD8⁺CD45RClow regulatory T cells that were capable of transferring the tolerant state to naive animals. However, cardiac transplants in these recipients systematically developed chronic rejection lesions. Whereas anti-CD28 Ab monotherapy only delayed acute rejection and failed to induce tolerance, coadministration of anti-CD28 Abs and CD40Ig resulted in the long-term acceptation of allografts without chronic rejection lesions in 60% of the recipients, reduced the level of intragraft mRNA transcripts for cytokines and immune factors, and fully abrogated alloantibody production. In addition, the nature of regulatory cells was modified: the CD8⁺CD45RClow clonotypic T cells described in the CD40Ig-treated animals could not be found in cotreated animals, and the other CD8⁺CD45RClow cells had no regulatory activity and a different cytokine expression profile. Instead, in cotreated recipients we found IDO-dependent non-T cells with regulatory activity in vitro. Thus, the addition of a short-term anti-CD28 treatment with CD40Ig resulted in decreased heart allograft chronic rejection lesions, complete inhibition of Ab production, and modified regulatory mechanisms. The Journal of Immunology, 2007, 179: 8164–8171.

The Journal of Immunology

Received for publication March 9, 2007. Accepted for publication October 1, 2007.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This was supported in part by Roche Organ Transplant Research Foundation Grant 466230972 (to B.V.).
2 C.G. and C.S. contributed equally to this report.
3 I.A. and B.V. are both senior and corresponding authors and are listed in alphabetical order.
4 Address correspondence and reprint requests to Dr. Bernard Vanhove or Dr. Ignacio Anegon, Institut National de la Santé et de la Recherche Médicale, Unité 643, Centre Hospitalier de l’Université de Nantes, Nantes, France

Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00

www.jimmunol.org

CD40Ig plus anti-CD28 Ab-treated allograft recipient displaying no histological lesions of chronic rejection; Treg, regulatory T cell.

CD40Ig plus anti-CD28 Abs and CD40Ig resulted in the long-term acceptation of allografts without chronic rejection lesions in 60% of the recipients, reduced the level of intragraft mRNA transcripts for cytokines and immune factors, and fully abrogated alloantibody production. In addition, the nature of regulatory cells was modified: the CD8⁺CD45RClow clonotypic T cells described in the CD40Ig-treated animals could not be found in cotreated animals, and the other CD8⁺CD45RClow cells had no regulatory activity and a different cytokine expression profile. Instead, in cotreated recipients we found IDO-dependent non-T cells with regulatory activity in vitro. Thus, the addition of a short-term anti-CD28 treatment with CD40Ig resulted in decreased heart allograft chronic rejection lesions, complete inhibition of Ab production, and modified regulatory mechanisms. The Journal of Immunology, 2007, 179: 8164–8171.

Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00

www.jimmunol.org

CD40Ig plus anti-CD28 Ab-treated allograft recipient displaying no histological lesions of chronic rejection; Treg, regulatory T cell.
CTLA4Ig, targeting CD28 might promote the development of regulatory mechanisms (15). Several studies have indeed demonstrated that the selective blockade of CD28 reduced T cell reactivity in autoimmunity (16, 17) and transplantation (18). In the rat, the J3319 modulating CD28-specific mAb (19, 20) induced tolerance to kidney (21, 22) but not to heart allograft (11, 23). However, in a rat model of chronic rejection after heart allograft it promoted long-term survival (23).

The purpose of the current study was to investigate the effect of selectively targeting CD28 in a model of chronic vascularized cardiac allograft rejection following CD40L blockade (10). We hypothesized that the modulation of CD28 expression, by allowing for conserved CTLA4-B7-1/B7-2 interactions, would lead to (or reinforce) regulatory mechanisms and consequently result in full allograft tolerance. Our results identify a critical role for the CD40-CD40L and CD28-B7 costimulatory pathways in the development of different regulatory mechanisms in rat. Coblockade of both pathways resulted in a form of tolerance not supported by Treg cells but associated with IDO-dependant suppressive cells in the non-T cell compartment.

Materials and Methods

Animals and cardiac allograft models

Eight- to 12-wk-old male Lewis.1W (LEW.1W, haplotype RT1a) and Lewis.1A (LEW. 1A, haplotype RT1b) congenic rats (Centre d’Elevage the Institut National de la Sante ´ et de la Recherche Me ´dicale (INSERM). Here have been performed in accordance with the institutional guidelines of the University of Wu¨rzburg, Wu¨rzburg, Germany). JJ319 was given at a dose of 1010 infectious particles (IP) in 150 µl, negative; and 3.2.3 (CD161), OX42 (CD11b/c), and OX12 (Ig κ-chain) mAb-reactive cells using magnetic beads (Dynal). CD8+CD45RClow T cells were purified from the spleen using a FACSaibur flow cytometer (BD Biosciences) as previously described (10).

Mice

Splenocytes or pure T cells were isolated from a given sample, and proliferation was measured by incorporation of [3H]thymidine. Results were expressed as the percentage (± SD after the subtraction of proliferation in the presence of culture medium) of proliferation of cells from treated recipients as compared with that of cells from control recipient animals. Alternatively, specific cpm (cpm of the assay from which is subtracted the cpm of stimulator plus APCs alone) are shown.

Quantitative RT-PCR

Messenger RNA transcript analysis was performed by real-time quantitative PCR. Total RNA was isolated using TRIzol (Invitrogen Life Technologies) and amplified using the SuperScript RNA amplification system (Invitrogen Life Technologies) according to the manufacturer’s instructions. Ten micrograms of RNA were reverse transcribed using a Moloney murine leukemia virus reverse-transcriptase kit (Invitrogen Life Technologies). Real-time quantitative PCR was performed with a GenAmp 7700 sequence detection system (Applied Biosystems) using SYBR Green PCR core reagents (Applied Biosystems). The following primer pairs were used: hypoxanthine phosphoribosyltransferase (HPRT; see Ref. 6); IFN-γ (see Ref. 6); IL-13 (see Ref. 6); IL-2; 5'-CCCTGTCACAGAGGGCACCC-3' and 5'-GCTGCCTCCCATTC-3'; TGFβ; 5'-CTGCTTGG-AGTCACGAGAGCCTCAGCA-3' and 5'-GGTCCCTAGGCACTTCTTCTGT-3'; IL-6; 5'-GCTTGACAGATGGCTATCC-3'; IL-2; 5'-CAGTGCTTGAGAA-3'; IL-10; 5'-GCTGCCTCCCATTC-3'; IL-2; 5'-CAGTGCTTGAGAA-3'; IL-10; 5'-GCTGCCTCCCATTC-3'; IL-23; 5'-AGGCAGAATTGACCAAGTGAC-3' and 5'-TCTGAGATGGTGTTGGTTCTC-3'; heme oxygenase-1 (HO-1; see 27); IDO, 5'-GGTCCTTAGCCACTCCTTCTG-3'; IL-6; 5'-CAGTGCTTGAGAA-3'; IL-10; 5'-GCTGCCTCCCATTC-3'; IL-23; 5'-AGGCAGAATTGACCAAGTGAC-3' and 5'-TCTGAGATGGTGTTGGTTCTC-3'; periforin; 5'-AGGCAGAATTGACCAAGTGAC-3' and 5'-TCTGAGATGGTGTTGGTTCTC-3'; C-reactive protein (CRP); 5'-AGGCAGAATTGACCAAGTGAC-3' and 5'-TCTGAGATGGTGTTGGTTCTC-3'; and glucocorticoid-induced TNFR-related protein (GITR), 5'-AGGCAGAATTGACCAAGTGAC-3' and 5'-TCTGAGATGGTGTTGGTTCTC-3'. The PCR method and the 2−ΔΔCt quantification method (where Ct is threshold cycle), after normalization to HPRT values, are shown.

Ab detection

Alloantibodies were analyzed by cytofluorometry following the incubation of Con A-activated allergenic spleen cells with diluted (1/10) heat-inactivated rat serum and then with biotin-conjugated F(ab')2 goat anti-rat IgG Abs (γ-chain specific) (Jackson ImmunoResearch Laboratories) or with a mouse anti-rat IgM mAb (MARM-7; Technopharm). Ab binding was revealed using FITC-coupled streptavidin or FITC-coupled F(ab')2 goat anti-mouse IgG (Jackson ImmunoResearch Laboratories). Levels of anti-SRBc Abs were assessed similarly using SRBC as targets. Cells were analyzed using a FACSaibur flow cytometer (BD Biosciences) and the results were expressed as mean channel fluorescence (MCF) for each serum.
Grubb’s test was used to determine outliers and p as determined by the gradient of the C_t injection of $10^{10}$ IP of the noncoding adenovirus Addl324 (n = 27). One group was treated with 4 mg/kg/day anti-CD28 mAb from day 0 to day 7 after transplantation (n = 11). One other group received a combined treatment with AdCD40lg ($10^{10}$ IP on day 0) and anti-CD28 (4 mg/kg/day from day 0 to day 7, n = 16). Graft survival was evaluated by daily palpation of heartbeat through the abdomen. * p < 0.05 vs untreated or Addl324-treated grafts; †, p < 0.05 vs anti-CD28.

Statistical analysis
Statistical significance was evaluated using the Mann-Whitney U test (analysis of two groups) or Kruskal-Wallis tests followed by a Dunn’s post hoc test (analysis of more than two groups) and a Kaplan-Meier analysis of graft survival (log-rank test); p ≤ 0.05 was considered significant. The Grubb’s test was used to determine outliers and p < 0.05 was considered significant.

**Results**
**Induction treatment with anti-CD28 Abs induces tolerance in a fraction of CD40lg-treated allograft recipients**
In the rat strain combination used here, monotherapy with an anti-CD28 mAb (JJ319) from day 0 to day 7 after heart transplantation resulted in a significant prolongation of allograft survival (18.7 ± 1.6, n = 11, p < 0.0001) as compared with untreated controls that uniformly rejected their graft (6.6 ± 0.5 days, n = 9) (Fig. 1). As previously shown (7), administration of CD40lg alone resulted in long-term allograft survival (>120 days, n = 27) in 93% of the recipients compared with recipients treated with the noncoding adenovirus (8 ± 0.8 days, n = 9). Treatment with anti-CD28 mAb in addition to the administration of CD40lg resulted in indefinite allograft survival in all recipients (Fig. 1).

A morphometric analysis of chronic rejection lesions performed 120 days after transplantation indicated that the grafts of CD40lg-transduced recipients, unlike syngenic grafts, displayed vascular lesions as well as mononuclear cell infiltration (Fig. 2). In the group treated with both CD40lg and anti-CD28 mAb, nine of the 16 grafts analyzed exhibited no vasculopathy (the pathognomonic lesions of chronic rejection), and the other seven displayed vascular chronic rejection lesions undistinguishable from those treated with CD40lg only. In all allograft recipients, however, a substantial level of fibrosis was noted (data not shown). The cotreated recipients displaying no chronic rejection lesions are thus operationally tolerant and are referred to as “Tol,” and those with chronic rejection lesions are called “CR” recipients.

**Graft infiltration and cytokine expression**
An immunohistological analysis showed that infiltrating cells in the allografts 120 days after transplantation represented up to 30% of the analyzed surface area in the CD40lg-treated recipients (Table I). The initial administration of anti-CD28 mAb to CD40lg-treated recipients decreased this cell infiltration. Infiltration in cotreated recipients usually represented only 1–5% of the analyzed surface area in these grafts whether or not the recipients presented chronic rejection lesions. One cotreated recipient displaying chronic rejection lesions, however, presented a slightly stronger infiltration that qualified as moderate (Table I). To analyze cytokine expression associated with tolerance and chronic rejection, total RNA was extracted from the allografts of CD40lg-treated and

<table>
<thead>
<tr>
<th>Group</th>
<th>OX1/OX30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naive</td>
<td>–, 0/+</td>
</tr>
<tr>
<td>Syngeneic</td>
<td>–, 0/–</td>
</tr>
<tr>
<td>AdCD40lg</td>
<td>++, +/++, ++, +, +++, +++, +++</td>
</tr>
<tr>
<td>AdCD40lg plus anti-CD28 Tol</td>
<td>+, +, +</td>
</tr>
<tr>
<td>AdCD40lg plus anti-CD28 CR</td>
<td>+, +, ++, +</td>
</tr>
</tbody>
</table>

*Graft biopsies were analyzed by immunostaining, and the intensity of the staining was evaluated according to an arbitrary scale and scored as follows: –, negative; +, weakly infiltrated (1 to 5% of the surface area); ++, moderately infiltrated (5 to 15% of the surface area); and ++++, strongly infiltrated (15 to 30% of the surface area). The recipients cotreated without chronic rejection lesions were thus operationally tolerant and are referred to as “Tol” and those with chronic rejection lesions as “CR”. Each symbol represents one graft.
CD40Ig plus anti-CD28 Abs-treated animals on day 120 posttransplantation. Transcripts for IL-6, perforin, and also for CTLA4, HO-1, TGF-β, IFN-γ, IL-2, and IL-10 transcription. Messenger RNA levels were normalized to the level of HPRT and expressed as the fold change relative to corresponding mRNA levels in syngeneic grafts. Individual observations (in AU) are reported with the horizontal bar representing the mean.

* p < 0.05; ** p < 0.01; *** p < 0.005.

Tolerant recipients treated with CD40Ig and anti-CD28 mAb displayed inhibited alloantibody responses

To assess the mechanisms by which the selective blockade of CD40-CD40L and CD28-B7 pathways resulted in the development of tolerance or chronic rejection lesions, serum levels of alloantibodies were measured in long-surviving recipients 120 days after transplantation. As previously shown (7), IgG alloantibody levels were reduced in the sera of CD40Ig-treated recipients with long-surviving grafts compared with those of control (Addl324)-treated recipients (Fig. 4). The CR recipients in the CD40Ig plus anti-CD28-treated group showed IgG levels not significantly different from those observed in CD40Ig alone-treated recipients. In contrast, this Ab response was considerably reduced and not different from the background in sera of Tol recipients. This reduction was statistically significant for total IgG (MCF of 341.9 ± 64.7 vs 23.3 ± 12.8, p < 0.05), IgG1 (127.6 ± 35 vs 11.6 ± 7.4, p < 0.05) and IgG2b (71.8 ± 16.6 vs 8.4 ± 0.9, p < 0.05).

Anti-CD28 mAb prevents immunization with SRBC in CD40Ig-treated animals

To analyze whether the absence of alloimmunization in Tol recipients was specific for alloantigens, we injected SRBC i.v. on the day of transplantation. Within 3 wk, CD40Ig plus 3G8 irrelevant Ab-treated recipients developed IgG and IgM anti-SRBC Abs, whereas CD40Ig plus anti-CD28 mAb-treated recipients did not develop any responses (Fig. 5).
Adoptive transfer of tolerance is modified by anti-CD28 mAb

We demonstrated previously that in CD40Ig-treated recipients of heart allografts, Treg cells from the spleen with a CD8+ CD45RClow phenotype are able to transfer tolerance to secondary grafted recipients (10). To determine whether anti-CD28 treatment influences the nature of these regulatory cells, we performed additional adoptive transfer experiments. LEW.1A rat recipients of LEW.1W heart transplants were sublethally irradiated (4.5 gray) and injected i.v. on day 0 with 2 × 10^8 spleen cells from Addl324, CD40Ig, or CD40Ig + anti-CD28 mAb-treated LEW.1A recipients of LEW.1W grafts. These spleen cells were collected >120 days after transplantation. Transfer of spleen cells from CD40Ig-treated recipients resulted in the indefinite survival of heart grafts in secondary recipients, demonstrating that regulatory cells in the spleen are sufficient for inhibiting rejection. In contrast, spleen cells from CD40Ig plus anti-CD28 Ab-treated recipients failed to induce any prolongation of survival after transfer (Fig. 6). This indicated that spleen cells from cotreated animals did not contain similar transferr-competent regulatory cells.

Cytokine expression by CD8+ CD45RClow T cells is modified in CD40Ig plus anti-CD28 mAb-treated animals

To further understand the functional differences in CD8+ CD45RClow T cell populations, we sorted these cells from the spleen of CD40Ig-treated and CD40Ig plus anti-CD28 mAb-treated animals on day 120 posttransplantation. An average of 5 × 10^6 CD8+ CD45RClow cells could be extracted from the spleens and the treatments did not modify this number. Total RNA was extracted from these cells, and transcripts for cytokines and regulatory proteins were analyzed by quantitative PCR. Transcripts for IFN-γ and TGFβ were significantly reduced in CD40Ig plus anti-CD28 mAb-treated recipients, as compared with CD40Ig treated alone recipients. The strongest difference appeared to be the expression of IFN-γ, because no expression could be measured in CD8+ CD45RClow T cells from cotreated animals. We found no correlation between the Tol (Fig. 7A, open symbols) or CR (Fig. 7A, filled symbols) status of the cotreated animals and the cytokine expression levels. The expression of transcripts for FoxP3 and GITR was not different between the two groups (Fig. 7A) as well as the expression of IL-13 and IL-4 (data not shown).
Anti-CD28 Abs prevent amplification of clonotypic CD8<sup>+</sup> CD45R<sub>Clow</sub> Treg cells

We had observed that heart transplant recipients treated with CD40lg developed an accumulation of the V<sub>B11</sub> family transcripts as well as an alteration of the Gaussian profile of the CDR3 length distributions in this V<sub>B</sub> family within the CD8<sup>+</sup> CD45R<sub>Clow</sub> T cell population, with an increased representation of transcripts with an 8-aa-long CDR3 (10). In this study, we determined that this accumulation did not occur in the CD8<sup>+</sup> CD45R<sub>Clow</sub> T cell population sorted from CD40lg-treated animals that also received anti-CD28 Abs (Fig. 7B), demonstrating that the public TCR response to common donor Ag(s) in the CD8<sup>+</sup> CD45R<sub>Clow</sub> regulatory T cells was absent.

IDO-dependant non-T cell-based regulatory mechanisms in tolerant recipients treated with CD40lg plus anti-CD28 mAb

To investigate regulatory mechanisms that might contribute to the tolerant state in the absence of transfer-competent regulatory T cells, the proliferative response of splenocytes from controls or CD40lg-treated recipients with or without anti-CD28 Abs was analyzed on day 120 posttransplantation. The splenocytes from long-surviving graft recipients consistently displayed decreased proliferative responses to donor-type APCs (27.4 ± 5, 52.2 ± 9.8, and 28.7 ± 14.2% for CD40lg, CR, and Tol cotreated recipients, respectively) as compared with Addl324-treated controls (considered as 100%, n = 6) (Fig. 8A). The unresponsiveness of spleen cells was not donor specific because it was also observed when third party BN APCs were used as stimulators (30.1 ± 6.3, 51.3 ± 8, and 42 ± 14.3% for CD40lg, CR, and Tol recipients, respectively) (Fig. 8A). In contrast with unfractionated splenocytes, the proliferation of purified T cells stimulated by donor and third party APCs showed no significant difference between the groups (Fig. 8B). These observations suggested that alloreactivity was controlled by non-T cells in the spleen and that the CD8<sup>+</sup> CD45R<sub>Clow</sub> T cells identified by transfer experiments have no suppressive activity in vitro under the conditions used here. To further characterize this regulatory mechanism dependent on non-T cells, we added 1-MT, an inhibitor of IDO, to the culture medium in coculture experiments, however spleen cells from the spleen (E) was assessed by adding a 1:2 cell ratio to naive MLR reactions consisting of LEW.1A splenocytes responding to irradiated LEW.1W or BN APCs. Proliferation was measured after 5 days by incorporation of [<sup>3</sup>H]thymidine during the last 8 h of the culture. In all experiments, cell viability was confirmed by the ability of the cells to proliferate upon ConA stimulation. Results in A, B, D, and E are the percentage (mean ± SD of three experiments) of cell proliferation relative to the proliferation of cells from Addl324-treated recipients. In these experiments, specific counts ranged between 30,000 and 100,000 cpm. Results in C are means of triplicates ± SD from one representative experiment of four and are expressed as specific cpm. Animals assigned as CR or Tol are represented separately in A, B, D, and E. *p < 0.05; **p < 0.01.

Discussion

In this study, we demonstrated that the perioperative addition of anti-CD28 Abs to CD40lg treatment reinforces the tolerance to a cardiac allograft and modifies the regulatory mechanisms. We previously demonstrated that the administration of CD40lg to heart transplant rat recipients induced CD8<sup>+</sup> CD45R<sub>Clow</sub> regulatory T cells in the spleen that were able to transfer tolerance to secondary recipients (10). In the present study we also observed in this model that despite their suppressive activity in vivo after transfer (Fig. 6), T cells from the spleen responded normally in a MLR (Fig. 8B) and had no regulatory activity in vitro (Fig. 8E). Because unfractionated spleen cells presented reduced proliferation capacities against APCs, we hypothesized that a control of alloreactivity should occur through the action of suppressive non-T cells. In coculture experiments, however, spleen cells from CD40lg-treated recipients had no suppressive activity on naive T cells (Fig. 8D). Thus, in vitro neither T cells nor non-T cells from CD40lg-treated recipients could block a naive MLR whereas the alloreactivity of recipient splenocytes was inhibited. This suggested a form of suppression active only on primed alloreactive T cells. In Tol recipients treated with anti-CD28 Abs in addition to CD40lg, the regulatory mechanism appeared different. First, the adoptive transfer of spleen cells failed to transfer tolerance to secondary recipients (Fig. 6). Second, the transfer-competent CD8<sup>+</sup> CD45R<sub>Clow</sub> Treg...
cells identified in CD40lg-treated recipients (10) presented a modified cytokine profile; they contained no messenger for IFN-γ and expressed low levels of TGFβ (Fig. 7A), two cytokines implicated in the suppressive activity of CD8+ T cells (32, 33). In contrast, they presented more transcripts for IL-10 and IL-2, possibly indicating an activated rather than a regulatory profile. Messenger RNA for TGFβ and IFN-γ were also found reduced in graft biopsies from anti-CD28 Abs plus CD40lg-treated recipients as compared with CD40lg treatment alone (Fig. 3), pertaining to the correlation between the expression of these cytokines, the presence of CD8+CD45RClow Treg cells, and their regulatory properties. In addition, the expansion of CD8+CD45RClow T cells with a Vβ11 CDR3-L8 clonotype was completely abrogated in CD40lg-treated recipients that also received anti-CD28 Abs (Fig. 7B). These data strongly support the idea that in CD40lg-treated graft recipients, clonotypic CD8+CD45RClow T cells are the major regulatory mechanism and that these cells do not develop if anti-CD28 Abs have been initially administered. A third observation pointing to differences between CD40lg and cotreated recipients was that the proliferation of alloreactive T cells from the spleen was repressed by non-T cells (Fig. 8, A and B) and that this was under the control of IDO in cotreated animals (Fig. 8C). Together, our data indicate that anti-CD28 Abs have induced a shift from a system where transfer-competent regulatory CD8+CD45RClow T cells presumably interacting with still undefined APCs in a tolerogenic manner control effector T cells to a situation where these cells have not been selected and where a suppression is supported only by IDO-dependent non-T cells.

It was previously demonstrated that CD28 is required for thymic central CD4+CD25+ Treg development (34) and homeostasis (35) but not for its suppressive function (36). For CD8+ Treg cells, a role of CD28 has not been clear so far; whereas CD8 cells can respond efficiently to Ag in the absence of CD28 costimulation, peripheral tolerance of CD8+ T cells does not occur in vivo in the absence of CD28 (37). In contrast, the expression of CD28 molecules is not necessary for CD8+ Treg generation after contact with B7+ iris pigment epithelial cells (38). Also, after induction therapy in transplantation, suppressive T cells of the CD8+CD28− phenotype have been described (39), but whether CD28 is initially required for their development was not elucidated. In addition, regulatory CD8+CD45RClow cells do not express detectable levels of CD28 (10). In this study we have demonstrated that CD8+CD45RClow T cells were present in similar numbers in the spleen but modified their cytokine expression profile and lost their regulatory activity in vivo when heart graft recipients were treated with anti-CD28 Abs in addition to CD40lg. The TCR repertoire analysis also demonstrated that anti-CD28 Abs prevented the expansion of regulatory CD8+CD45RClow T cells in cotreated animals. Therefore, although the majority of CD8+CD45RClow cells from CD40lg-treated animals are CD28+ (10), it is possible that they originate from CD8+CD28+ cells and that the anti-CD28 mAb used here directly interfered with the acquisition of the regulatory properties of CD8+CD45RClow cells.

Heart allografts in recipients treated with CD40lg were still strongly beating 4 mo posttransplantation but systematically presented vasculitis and cell infiltration, the pathogenic characteristics of CR. This indicated that treatment with CD40lg inhibited acute graft rejection but did not induce full transplant tolerance. In comparison, 50–60% of heart allografts cotreated with anti-CD28 mAb had no lesions of CR and were thus fully tolerated, excepting that they still presented substantial levels of fibrosis. The remaining 40% of heart allografts, presenting CR lesions despite the cotreatment, could not be distinguished from the tolerant recipients by virtue of their anti-mouse Ab response that could otherwise blunt the immunoregulatory effect of anti-CD28 Abs (data not shown). Also, the circulating levels of CD40lg were similar in Tol and CR cotreated recipients (in all cases >100 μg/ml in the serum on day 10; data not shown). Cellular infiltration and intragraft cytokine expression were reduced in grafts from recipients treated with CD40lg plus anti-CD28 Abs as compared with CD40lg treatment alone, whether or not these grafts were found to be devoid of vascular lesions. Infiltration and cytokine expression levels therefore do not seem to be critical parameters correlated with vasculopathy. Rather, alloantibodies were found absent in Tol recipients while they were low but detectable in CR recipients (Fig. 4). It has been previously suggested that Ab induction (40) and chronic allograft vasculopathy (4, 7) are driven primarily by costimulation-dependent adaptive immunity that, in the context of CD40L blockade, might be driven by CD28. Blocking CD28 should therefore be effective in controlling pathogenic costimulation pathway activation and in preventing alloantibody production and chronic allograft vasculopathy. This effect on Ab responses was not restricted to alloantigens, because the coadministration of anti-CD28 Abs with CD40lg also abrogated Ab responses to SRBC (Fig. 5). The data presented here confirm, in the context of transplantation, a synergy between CD40lg and anti-CD28 Abs in inhibiting Ab responses.

Inhibiting the CD28-B7 pathway by using anti-CD28 Abs might result in a different outcome than with B7 antagonists such as CTLA4Ig. Indeed, B7 molecules also interact with CTLA4, leading to a direct repression of T cell responses (41) and to the synthesis of IDO by dendritic cells (12). We therefore hypothesized that blocking CD28 and not B7 might reinforce immunosuppression and promote tolerance. The in vivo relevance of an unopposed CTLA4-B7 interaction for transplant tolerance has been illustrated by experiments showing that CTLA4 blockade prevents tolerance induction (14, 42). We observed here an impact of CD40lg plus anti-CD28 Abs on chronic rejection, whereas in heart transplantation in mice anti-CD40lg plus CTLA4-Ig treatment did not result in the complete abrogation of CR (3). Therefore, blocking B7 results in a different outcome in transplantation than blocking CD28, although this is probably also model dependent.

In conclusion, following heart transplantation in the rat treated with CD40lg, anti-CD28 Abs modified the properties of CD8+CD45RClow cells, blunted Ab responses, and reduced the expression of CR lesions. It seems that the loss of CD8+CD45RClow T cell-based regulation does not account for the reduction of CR lesions, because both parameters were not correlated; all CD40lg plus anti-CD28 cotreated recipients presented an absence of suppressive CD8+CD45RClow T cells whereas 40–50% still presented CR lesions. Rather, a reinforced regulatory activity in the non-T cells compartment and the absence of a specific Ab response are the parameters most clearly associated with an absence of CR lesions.

Acknowledgments
We are grateful to Helga Smit, Bernard Martinet, and Emmanuel Merieau for animal care. We thank the Vector Core of the University Hospital of Nantes (Nantes, France), supported by the Association Française Contre les Myopathies, for producing the adenoviral vector used in this study. We thank TcLand S. A. for TcLandscape analyses.

Disclosures
The authors have no financial conflict of interest.

References


